Abstract:OBJECTIVE. The purpose of this work was to compare the predictive accuracy of alternative risk-assessment strategies used to screen for the risk of significant neonatal hyperbilirubinemia. PATIENTS AND METHODS. We conducted a prospective cohort study of 823 term and near-term newborns admitted to the well-infant nursery at the Hospital of the University of Pennsylvania. Maternal, infant, and delivery risk factors for significant hyperbilirubinemia were obtained from chart review, structured interviews with parents, and nurse assessments before discharge. Transcutaneous bilirubin measurement was performed daily until discharge and once by a visiting home nurse between 3 and 8 days of life. We used the c statistic to compare the predictive accuracy of 3 risk-assessment strategies for estimating the risk of significant neonatal hyperbilirubinemia, defined as a bilirubin level that at any time after birth exceeded or was within 1 mg/dL (17 μmol/L) of the hour-specific phototherapy treatment threshold recommended by the American Academy of Pediatrics in 2004. The compared strategies included those that use (1) a predischarge bilirubin level (obtained before 52 hours) expressed as a risk zone on an hour-specific bilirubin nomogram, (2) clinical risk factors other than the predischarge bilirubin level, and (3) a combination of the predischarge bilirubin risk zone and additional clinical risk factors. RESULTS. Forty-eight patients (6%) developed significant neonatal hyperbilirubinemia. The predischarge (<52 hours) bilirubin level expressed as a risk zone on the bilirubin nomogram and a prediction model that combined multiple other clinical risk factors had similar accuracy for predicting significant hyperbilirubinemia. The only clinical risk factor that could be added to the predischarge risk zone to improve overall predictive accuracy was gestational age. The predischarge bilirubin risk zone and gestational age could be used to stratify patients into a large group (n = 523 [70%]) of infants with a very low (0.2%) risk of developing significant hyperbilirubinemia, a small group of infants (n = 127 [17%]) with a low (4%) risk of developing significant hyperbilirubinemia, and an even smaller group of infants (n = 100 [13%]) with a high (42%) risk of developing significant hyperbilirubinemia. CONCLUSIONS. An infant's risk of developing significant hyperbilirubinemia can be simply and accurately assessed by using just the infant's predischarge bilirubin level and gestational age.

Neonatal hyperbilirubinemia management: Clinical assessment of bilirubin production.

An End-Tidal Carbon Monoxide Nomogram for Term and Late-Preterm Chinese Newborns.

Neonatal Bilirubin Binding Capacity Discerns Risk of Neurological Dysfunction

Clinical Features of 116 Near Term and Term Infants with Acute Bilirubin Encephalopathy in Eastern China

Research Progress of Bilirubin-Induced Brain Injury in Preterm Neonate

Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels.

A Clinical Prediction Rule for Acute Bilirubin Encephalopathy in Neonates with Extreme Hyperbilirubinemia A Retrospective Cohort Study

Neonatal/perinatal diagnosis of hemolysis using ETCOc

Clinical analysis of 1 082 cases of neonatal hyperbilirubinemia

Analysis of High Risk Factors in 210 Neonates with Hyperbilirubinemia

A Comparison of Alternative Risk-Assessment Strategies for Predicting Significant Neonatal Hyperbilirubinemia in Term and Near-Term Infants

Neonatal Hyperbilirubinemia: Evaluation and Treatment

Clinical and Genetic Etiologies of Neonatal Unconjugated Hyperbilirubinemia in the China Neonatal Genomes Project.

Bilirubin measurements in neonates: uniform neonatal treatment can only be achieved by improved standardization

Transcutaneous bilirubin nomogram for predicting neonatal hyperbilirubinemia in healthy term and late-preterm Chinese infants

Analytical Performance Validation and Clinical Application of Blood Gas Analyzer on the Detection of Neonatal Bilirubin

Clinical Analysis of Neonatal Severe Hyperbilirubinemia

Technical Report: Diagnosis and Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.

Progress of neonatal severe hyperbilirubinemia therapies

Close Monitoring of Transcutaneous Bilirubin Ensures Better Outcome in Neonates with Hyperbilirubinemia

Advances in Treatment of Neonatal Hyperbilirubinemia